A simplified procedure was developed for the determination of granisetron (GRN), a selective 5-HT: receptor antagonist, in human plasma by high-performance liquid chromatography. The procedure involves elution of GRN from plasma by solid-phase extraction prior to reversed-phase chromatographic separation on a cyano propyl silica column with subsequent quantification with a fluorescence detector. Using 1 ml of plasma sample, linear responses in concentration-peak area ratios were observed to range from 0.1 to 25.0ng/ml plasma. The coefficient of variance value of the measurement was below 5 % across the calibration range, and the recovery of GRN from plasma reached 98%. The assay method was applied to determine the plasma level of GRN in healthy adults after a single oral administration (2mg), followed by analysis according to a 2-compartment open model employing first-order absorption. This method was found to be useful to support drug monitoring and pharmacokinetic studies for GRN.
Introduction
Granisetron (GRN) is a selective antagonist of 5-HT3 receptors, which structure comes from mimic of cocaine and hydroxytryptamine. (Fig.1) It has dramatically improved vomiting or nausea induced by cytotoxic drugs.1) Recently in Japan, the tablet form of GRN has been commercial, which has the merits that it is easy to administer and available for outpatients in the chemotherapy with anticancer drugs. On the other hand, GRN has been described to have the adverse effects included headache, somnolence, and diarrhea or, conversely in some patients, constipation.2,3) We consider it of clinical importance to examine the effective concentration ranges and the correlation between plasma levels and clinical manifestations, however, there were a few reports about them. Although HPLC methods were described for the quantification of GRN, they seemed to be somewhat complicated. In this work, we aimed to develop a simple and stable assay method for GRN to apply drug monitoring and pharmacokinetic studies. were different from those reported. This reason would come not from the differences of total number of the subjects but from those of methodology on calculations for pharmacokinetic parameters.
In conclusion, this assay method was shown to be simple, quick and reliable one, and fully available for drug monitoring and pharmacokinetic studies in both normal and patient populations. 
